Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Tuesday, November 24, 2009, 4:11am EST - Canadian Markets open in 5 hours and 19 minutes.
To create a watchlist or portfolio of shares,
Sign-in
or
Register
Finance Home
Investing
Volume Leaders
Local Markets
US Markets
International Markets
Advances & Declines
ETFs
Income Trust News
News & Opinion
Markets
Industry
RSS-My Yahoo!
Personal Finance
Banking & Budgeting
Calculators
Insurance
Retirement
Taxes
My Portfolios
Sign In to Create/Edit My Portfolios
Get Quotes
Symbol Lookup
Exchanges
Novogen Limited (NVGN)
On Nov 23:
2.45 USD
0.00 (0.00%)
MORE ON NVGN
Quotes
Summary
Options
Historical Prices
Charts
Interactive
Basic Chart
Technical Chart
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Major Holders
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheets
Cash Flow
Novogen Limited
(NGM:NVGN) Delayed quote data
Last Trade:
2.45 USD
Trade Time:
Nov 23
Change:
0.00 (0.00%)
Prev Close:
2.45
Open:
N/A
Bid:
N/A
Ask:
N/A
1y Target Est:
N/A
Day's Range:
N/A - N/A
52wk Range:
1.23 - 7.00
Volume:
0
Avg Vol
(3m)
:
24,212.3
Market Cap:
50.04M
P/E
(ttm)
:
N/A
EPS
(ttm)
:
-0.88
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Add NVGN to Portfolio
Download Data
HEADLINES
The Complete List of Australian ADR Stocks
at Seeking Alpha
(Fri, Nov 6)
Lee Enterprises, Novogen: Biggest Price Gainers (LEE, NVGN)
at The Wall Street Journal Online
(Tue, Sep 29)
Marshall Edwards, Inc.'s NV-128, a Novel mTOR Inhibitor, Demonstrates Good Safety Profile and High Anti-Cancer Activity In Vivo
Marketwire
(Tue, Sep 29)
Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Bid Price Non-Compliance
Marketwire
(Tue, Sep 22)
NOVOGEN LTD Financials
EDGAR Online Financials
(Tue, Aug 18)
Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
Marketwire
(Wed, Aug 5)
Novogen Director Retires
Marketwire
(Thu, Jul 30)
Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells
Marketwire
(Tue, Jul 7)
Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial
Marketwire
(Wed, Jun 17)
Novogen's NV-128 Targets the mTOR Pathway to Block Differentiation and Induce Cell Death in Ovarian Cancer Stem Cells
Marketwire
(Mon, Apr 20)
Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial
Marketwire
(Tue, Apr 14)
More Headlines for NVGN...
ANALYST
EPS Est (next year)
(Dec-69)
:
N/A
EPS Est (in 2 years)
(Dec-69)
:
N/A
Avg Rec (current)*:
1.0
PEG Ratio:
N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
Novogen Limited and its subsidiaries engage in the research and development of pharmaceutical products, and marketing of consumer healthcare products. The companys consumer healthcare products comprise Promensil, a range of natural products ...
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Symbol Lookup
Latest News
Canadian Indices